Barclays keeps USD 12.00 target for REGENXBIO stock

Published on 10/17/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 108.02 million. REGENXBIO stock cost EUR 6.30 on October 16, 2026, up 4.83 percent versus Frankfurt close.

Analyst view and market levels

On October 13, 2026, Barclays kept a Hold rating and a USD 12.00 target for REGENXBIO.
Second-quarter 2026 revenue reached USD 108.02 million against USD 97.63 million expected.
REGENXBIO stock stood at EUR 6.30 at 8:01 a.m. CEST on October 16, 2026, 4.83 percent above the Frankfurt close of October 15, 2026.
REGENXBIO had a negative P/E of -1.83 and a USD 457.1 million market capitalization on October 16, 2026.

RGNX, US75901B1070, Illustration mit AI erstellt.

Barclays kept a Hold rating and a USD 12.00 price target for REGENXBIO on October 13, 2026, according to Business Insider. The target stood 73.16 percent above the USD 6.93 Nasdaq closing price reported for October 16, 2026. The last Frankfurt quote was EUR 6.30 at 8:01 a.m. CEST on October 16, 2026, up 4.83 percent from the Frankfurt close of EUR 6.01 on October 15, 2026.

Second-quarter revenue exceeded consensus

REGENXBIO reported USD 108.02 million in revenue for the second quarter of 2026, compared with a USD 97.63 million consensus estimate. MarketBeat also reported adjusted earnings of USD 0.43 per share against a consensus estimate of USD 0.08 for that period. The company generated USD 22.71 million in consolidated net income in the second quarter, after a USD 90.05 million net loss in the first quarter.

EUR 6.30 quote and range

The Frankfurt quote sat within a EUR 4.83 to EUR 13.00 52-week range on October 16, 2026. That placed the quote EUR 1.47 above the range low and EUR 6.70 below the high. The Nasdaq quote was USD 6.93 at the October 16 close, while average daily volume was 1,377,312 shares and the latest session volume was 1,210,187 shares.

Valuation and October 20 event

REGENXBIO had a negative P/E of -1.83 and a market capitalization of USD 457.1 million on October 16, 2026. The investor calendar lists a wet age-related macular degeneration event for October 20, 2026, focused on surabgene lomparvovec and its clinical program, according to REGENXBIO. The company develops gene therapies through its adeno-associated virus platform, with RGX-314 in Phase III trials for wet age-related macular degeneration.

On October 15, 2026, REGENXBIO stock closed near USD 6.88 after trading below its 50-day moving average of USD 8.89, as MarketBeat reported.

Comparison with peers

On October 16, 2026, the available peer figures were:

REGENXBIO (Nasdaq, USD): plus 4.83 percent, P/E -1.83, market capitalization USD 457.1 million
Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E -5.90, market capitalization USD 1.8 billion
Rocket Pharmaceuticals (Nasdaq, USD): minus 7.63 percent, P/E -12.82, market capitalization USD 239.3 million

Market frame for RGNX

The last Frankfurt quote was EUR 6.30 at Lang and Schwarz on October 16, 2026 at 8:01 a.m. CEST, 4.83 percent above the Frankfurt close of October 15, 2026 at EUR 6.01.